NCT07085806 To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery
| NCT ID | NCT07085806 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Condition | Liver Regeneration |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2025-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-01-01 with a primary completion date of 2025-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Posthepatectomy liver failure (PHLF) remains a significant life-threatening problem after major hepatectomies. Pentoxifylline is shown to have potent vasodilating properties for peripheral blood vessels, along with the hepatic vasculature. In a Double-blinded, randomized, controlled trial (RCT) at a single tertiary care center (2006-2009) by Petrowsky, Henrik et al (Annals of Surgery, November 2010) on 101 Non-cirrhotic patients undergoing major Hepatectomy, they demonstrated beneficial effects of Pentoxifylline on regeneration of small remnant livers (RLBW ratio ≤ 1.2%). In mice model, pentoxifylline (Tian, Yinghua, et al Proceedings of the National Academy of Sciences 103.12 (2006)) is shown to confer protective effects against small-for-size syndrome in arterialized small-for-size liver transplantation. This Randomised control trial is being conducted to analyze the effect of Pentoxifylline supplementation in live donors undergoing donor hepatectomy with respect to markers of anatomical regeneration in a high volume liver transplant center in India.
Eligibility Criteria
Inclusion Criteria: * All live donors undergoing Right Donor Hepatectomy after ethical board clearance in the Department of HPB Surgery and Liver Transplantation Exclusion Criteria: * Negative consent Hypersensitivity to Pentoxifylline
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07085806 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Liver Regeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07085806 currently recruiting?
Yes, NCT07085806 is actively recruiting participants. Contact the research team at parneet.sunam@gmail.com for enrollment information.
Where is the NCT07085806 trial being conducted?
This trial is being conducted at New Delhi, India.
Who is sponsoring the NCT07085806 clinical trial?
NCT07085806 is sponsored by Institute of Liver and Biliary Sciences, India. The trial plans to enroll 60 participants.